Related Experiment Videos
European experience with oral solution and intravenous itraconazole
1Department of Hematology, Royal Free Hospital, London, United Kingdom. m.potter@rfc.ucl.ac.uk
Oncology (Williston Park, N.Y.)
|January 5, 2002
Summary
New itraconazole formulations offer effective prevention and treatment for fungal infections in immunocompromised patients, showing promise against Aspergillus and Candida species with reduced toxicity compared to older antifungals.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Fungal infections pose a significant threat to immunocompromised patients, particularly those with hematologic malignancies.
- Traditional antifungal agents like amphotericin B have limitations due to toxicity.
- Itraconazole offers a broad spectrum of activity against key fungal pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of new oral and intravenous (IV) itraconazole formulations.
- To compare itraconazole with existing treatments like amphotericin B and fluconazole.
- To assess itraconazole's role in prophylaxis, empiric therapy, and treatment of invasive fungal infections.
Main Methods:
- Review of European studies evaluating itraconazole in neutropenic patients.
- Analysis of treatment outcomes for invasive pulmonary aspergillosis with IV followed by oral itraconazole.
- Comparison of empiric itraconazole therapy with amphotericin B.
- Assessment of oral solution prophylaxis studies.
Main Results:
- IV followed by oral itraconazole achieved response or stable disease in two-thirds of patients with invasive pulmonary aspergillosis.
- Empiric itraconazole demonstrated comparable efficacy and significantly lower toxicity than amphotericin B.
- Oral itraconazole prophylaxis proved effective in preventing fungal infections.
- Itraconazole exhibits broader in vitro activity than fluconazole against Aspergillus and non-albicans Candida species.
Conclusions:
- Improved oral and IV itraconazole formulations are valuable for prophylaxis, empiric therapy, and treatment of fungal infections.
- Itraconazole presents a favorable alternative to amphotericin B due to reduced toxicity and comparable efficacy.
- Itraconazole's broad-spectrum activity and improved formulations enhance its utility in managing fungal infections in immunocompromised populations.